Articles Tagged With:
-
Clinical Briefs
In this section: Reconsidering the value of oral nutritional supplementation in patients admitted for COPD; recognizing a relationship between asthma and obesity; and weighing the benefits of sound stimulation in Alzheimer's patients.
-
Eluxadoline Tablets (Viberzi) and Rifaximin (Xifaxan) Tablets
Both drugs appear to provide modest benefit in irritable bowel syndrome with diarrhea.
-
Statin Use and Cognitive Effects: Not a Brain Drain
A meta-analysis of data from more than 28,000 patients enrolled in 18 randomized, placebo-controlled trials of statin therapy failed to show a causal relationship between treatment and adverse neurocognitive effects for patients with and without cognitive impairment.
-
Prostate Cancer and Smoking: One More Reason to Trash the Tobacco
Study showed that following prostatectomy for cancer, smokers and ex-smokers had a higher risk of recurrence.
-
You Are What You Feed Your Gut Microbiome
There is mounting evidence that the gut microbiome influences the immune system and the central and peripheral nervous systems.
-
ED Push - August 2015 Second Issue
-
The “Choosing Wisely”® Campaign: An Evidence-Based Review of the Recommendations: Part II
This issue finishes our discussion of the 10 ACEP recommendations for the Choosing Wisely® campaign.
-
Serum Chloride Level Predicts Mortality in Acute Heart Failure
Serum chloride levels measured during hospitalization for acute decompensated heart failure are independently and inversely associated with long-term mortality, independent of serum sodium levels.
-
New Study Calls for Caution in Use of Triple Anticoagulant Therapy
Approximately one in four older patients with atrial fibrillation undergoing percutaneous coronary intervention for acute myocardial infarction were discharged on triple therapy, which was associated with higher rates of major bleeding without a measurable benefit in terms of major adverse cardiac events.
-
RITA-3 Reports 10-year Mortality Outcomes: Time to Rethink the Guidelines, or Much Ado About Nothing?
The mortality benefit of the routine early invasive strategy seen at 5 years is attenuated at later follow-up, suggesting further trials of more contemporary treatment strategies in non-ST elevation acute coronary syndromes are needed.